OBJECTIVE: To develop benchmark methodology for identifying gout patients and acute attacks, prevalence, patient characteristics, and rate of gout attacks from MCO data. METHODS: This retrospective study was in a 1.1 million southeastern US MCO. Patients had ≥2 visits with ICD-9 code for gout (274.xx) or ≥1 pharmacy script(s) for allopurinol, colchicine, probenecid, or sulfinpyrazone between January 1, 2000 and December 31, 2002 (intake period). Patients on allopurinol without an ICD-9 code for gout were excluded if they had neoplasm or nephrolithiasis. First gout claim/script within the intake period was the index date. Patients ≥18 years with continuous eligibility for oneyear pre and post index date were included. Gout attack was defined as office or ER visit with medical claim for gout or joint pain (ICD-9 719.4x) and ≥1 of the following within seven days but not within six months prior: new pharmacy claim for NSAID, colchicine, corticosteroid, ACTH, intra-articular aspiration/injection, or microscopy of joint fluid. Statistical analysis was performed on continuous and categorical variables. RESULTS: A study cohort of 5942 gout patients was identified with prevalence rate of 1.6%. In this database, gout patients were relatively older (mean age 57 ± 14 years), predominantly male (76%), suffered from substantial cardiovascular pre-index comorbidities (hypertension [40%], CHD [25%]), diabetes (18%), and renal impairment (5%). Nineteen percent (1121/ 5942) of patients had ≥1 gout attack. Among the gout attack subset, median rate of attacks per patient per year was 0.57 (range 0.24 to 6.9). CONCLUSION: Patients with gout were older, predominantly male, and had high rates of cardiovascular comorbidities. The prevalence rate identified is similar to other estimates in the literature. Further research is necessary to refine and validate our methodology since this work did not address self-managed gout attacks.
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only addressed absenteeism ± disability without regards to presenteeism; true productivity costs are likely even higher than reported. Cost assessment measures in clinical trials for fibromyalgia need to be determined. HealthCore, Inc, Wilmington, DE, USA; 2 TAP Pharmaceuticals, Inc, Lake Forest, IL, USA OBJECTIVE: To develop benchmark methodology for identifying gout patients and acute attacks, prevalence, patient characteristics, and rate of gout attacks from MCO data. METHODS: This retrospective study was in a 1.1 million southeastern US MCO. Patients had ≥2 visits with ICD-9 code for gout (274.xx) or ≥1 pharmacy script(s) for allopurinol, colchicine, probenecid, or sulfinpyrazone between January 1, 2000 and December 31, 2002 (intake period). Patients on allopurinol without an ICD-9 code for gout were excluded if they had neoplasm or nephrolithiasis. First gout claim/script within the intake period was the index date. Patients ≥18 years with continuous eligibility for oneyear pre and post index date were included. Gout attack was defined as office or ER visit with medical claim for gout or joint pain (ICD-9 719.4x) and ≥1 of the following within seven days but not within six months prior: new pharmacy claim for NSAID, colchicine, corticosteroid, ACTH, intra-articular aspiration/injection, or microscopy of joint fluid. Statistical analysis was performed on continuous and categorical variables. RESULTS: A study cohort of 5942 gout patients was identified with prevalence rate of 1.6%. In this database, gout patients were relatively older (mean age 57 ± 14 years), predominantly male (76%), suffered from substantial cardiovascular pre-index comorbidities (hypertension [40%], CHD [25%]), diabetes (18%), and renal impairment (5%). Nineteen percent (1121/ 5942) of patients had ≥1 gout attack. Among the gout attack subset, median rate of attacks per patient per year was 0.57 (range 0.24 to 6.9). CONCLUSION: Patients with gout were older, predominantly male, and had high rates of cardiovascular comorbidities. The prevalence rate identified is similar to other estimates in the literature. Further research is necessary to refine and validate our methodology since this work did not address self-managed gout attacks. RESULTS: RA had significantly more mean annual hospitalizations: 0.27 (SD0 .61) vs. 0.16 (SD 0.51), p = 0.025; mean annual medications purchased :34 (SD27) vs. 27.5 (SD 27) p = 0.01; mean annual medical visits 19 (SD11) vs. 14.5 (SD 14) p < 0.001, and outpatients procedures 48 (SD37) vs. 31 (SD 25); p < 0.001. RA patients also had significantly more mean total direct medical costs than general population ($752 vs. $557; p = 0.006). Components of direct medical costs were: medical visits: 13%, medications: 24%, hospitalizations: 38% and outpatient procedures: 25%. Only one patient was on biologic treatment. There were no differences in costs between seropositive and seronegative patients, males or females or in relation to disease duration. CONCLUSIONS: RA patients used significantly more health care resources and were significantly more costly than the general population of same age and sex. In a developing country with scarce use of biologic therapy, direct medical costs are still mainly driven by hospitalizations.
PAR5 DEVELOPMENT OF BENCHMARK METHODOLOGY TO IDENTIFY GOUT PATIENTS AND GOUT ATTACKS FROM

ARTHRITIS-Rheumatoid
PAR7 SURVEY OF CURRENT TREATMENT PRACTICES OF RHEUMATOLOGISTS IN PRESCRIBING TUMOR NECROSIS FACTOR INHIBITORS IN PATIENTS WITH RHEUMATOID ARTHRITIS
Kamal KM, Madhavan SM, Hornsby JAA West Virginia University, Morgantown, WV, USA OBJECTIVES: To determine rheumatologists' current prescribing practices, laboratory monitoring protocols, and perceived barriers to prescribing Tumor Necrosis Factor (TNF) inhibitors (adalimumab, etanercept, and infliximab) in patients with rheumatoid arthritis (RA). METHODS: A survey questionnaire was mailed to 1970 rheumatologists who were randomly selected from a national sample of 3007 rheumatologists. A one-page nonresponse questionnaire was mailed to about 200 randomly selected nonresponding rheumatologists to assess nonresponse bias. RESULTS: Two mailings yielded a response rate of 22.2% (428 completed, usable surveys out of 1925 deliverable surveys). Rheumatologists reported using all three agents in patients with moderate RA (82-87%) and severe RA (94-96%). Also, some rheumatologists (10-18%) reported using these agents in newly diagnosed and mild RA patients. Sixty eight percent preferred etanercept as first choice TNF inhibitor while 28.5% and 20.3% preferred adalimumab and infliximab as first choice TNF inhibitors, respectively. In patients with severe RA and an inadequate response to methotrexate, 91% rheumatologists reported using TNF inhibitor with one other disease modifying anti-rheumatic drug (DMARD) and 27.9% reported using TNF inhibitor with two other DMARDs. Over 94% rheumatologists stated switching patients from one TNF inhibitor to a different TNF inhibitor due to inadequate response or side effects. Most rheumatologists ordered purified protein derivative test (96%) when administering these agents with almost 82% conducting this test at baseline. Other tests ordered were complete blood count, chest radiography, antinuclear antibody, and creatinine during baseline and follow-up of patients. Costs to the patients and insurance coverage were perceived as major barriers to prescribing these agents although the perception was a little lower with infliximab than with adalimumab or etanercept. CONCLUSIONS: Rheumatologists are fairly similar in their use of the three different TNF inhibitors although some variation
